E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Type 2 diabetes mellitus and diastolic heart faliure |
|
E.1.1.1 | Medical condition in easily understood language |
Type 2 Diabetes patients with impaired filling ability of the heart. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10069211 |
E.1.2 | Term | Diastolic heart failure |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this trial is to test if 18 weeks of treatment with liraglutide (up to 1.8 mg s.c. once daily) improves (or worsens) diastolic performance in T2DM patients with diastolic dysfunction, compared to placebo. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this trial are to evaluate whether 18 weeks of treatment with liraglutide (up to 1.8 mg s.c. once daily) improves (or worsen) myocardial perfusion and echocardiographic indices of diastolic dysfunction in T2DM patients with diastolic dysfunction, compared to placebo. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male or female patient fully capable of informed consent • Informed consent • Age 18-80 years (both years inclusive) • T2DM diagnosed at least 3 months • NYHA class I-III • E/e* ≥ 9 or e* (lateral) ≤10 cm/sec, or both • LVEF > 50% • LVEDV/BSA < 97 ml/m2 • Stable on heart medication for 6 weeks prior to randomization • Stable on antidiabetic treatment for 30 days prior to randomization • T2DM must be either treated with one or more oral anti-diabetic drugs or treated with human NPH-insulin or long-acting insulin analogue, alone or in combination with oral drugs |
|
E.4 | Principal exclusion criteria |
• Lack of consent. • NYHA class IV • Type 1 diabetes mellitus • Incretin-based therapy (GLP-1 receptor agonists; exenatide, liraglutide or other and DPP-IV inhibitors) within 30 days prior to randomization • Glitazon therapy within 30 days prior to randomization • Hypertension with inadequate blood pressure control: Systolic blood pressure > 140 mmHg and/or diastolic blood pressure >85 mmHg • Supine systolic blood pressure <85 mmHg • Significant valvular heart disease • Hypertrophic cardiomyopathy, ARVC/D, non-compaction or amyloidosis • Myocardial infarction, unstable angina, angina on exertion (≥CCS class 2) or coronary revascularization within 3 months prior to randomization • Hospitalisation due to incompensated heart disease within 30 days to randomization • HbA1c >10% • eGFR< 60 ml/min/1,73 m2 • Liver disease with aspartate aminotransferase/alanine aminotransferase >3 times upper limit of normal • Hypokalaemia (P-potassium <3.5 mmol/L) or hyperkalaemia (P-potassium >5.5 mmol/L) • Anaemia (haemoglobin <6.5 mmol/L) • Conditions that may be associated with changes in markers of fibroses or collagen turnover (eg. on-going or active rheumatological disease requiring anti-inflammatory agents, immunosuppression, pulmonary fibrosis, active cancer) • Prolonged use (> 2 weeks) of glucocorticoids or NSAIDs within 2 weeks prior to the beginning of the trail • Women of childbearing potential who are not on acceptable contraception • Pregnant or breastfeeding women • Cancer (except basal cell skin cancer or squamous cell skin cancer) unless complete remission for ≥ 5 years • Alcohol/drug abuse • Chronic or previous acute pancreatitis • History of thyroid adenoma or carcinoma • Inflammatory bowel disease • Clinical signs of diabetic gastroparesis • ICD/pacemaker or other contraindications to MRI scan • Severe claustrophobia • Atrial fibrillation • Contraindications to glycopyrrolate: closed-angle glaucoma, prostate hyperplasia, tachycardia at rest, bladder atony, cardia insufficiency, non-congenital pylorus stenosis and gastroparesis • Known or suspected hypersensitivity to trial product or related products • Current participation in any other clinical intervention trial • Receipt of an investigational drug with 30 days prior to the beginning of the trail • Other concominant disease or treatment that according to investigator’s assessment makes the patient unsuitable for participation in the study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoints will be change in diastolic properties as assessed by cardiac MRI: • LA passive emptying fraction (%) • LV peak filling rate (LVPFR) (ml/s)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Measured during week 18 (on medication, placebo/liraglutide) and compared to baseline (before placebo/liraglutide treatment is started) |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints consist of changes in: • MRI indices of myocardial perfusion • echocardiographic indices of diastolic dysfunction |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Measured during week 18 (on medication, placebo/liraglutide) and compared to baseline (before placebo/liraglutide treatment is started) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |